MK-677

Status

In trials. No FDA-approved product. As LUM-201 (ibutamoren) it is in a Phase 3 trial in children with growth hormone deficiency (NCT06948214: recruiting, planned 150, no results posted). It is prohibited in sport by WADA.

What it is

An oral small molecule — not a peptide and not a SARM — that activates the ghrelin receptor (GHSR) in the hypothalamus and pituitary, raising growth hormone and, downstream, IGF-1 from the liver.

What published research measured

In Nass et al. 2008 (older adults, 12 months), fat-free mass rose but strength and function did not improve, and fasting glucose rose with reduced insulin sensitivity. FDA documents record heart-failure, fluid-retention and glucose concerns.

Source

Nass et al. 2008, Annals of Internal Medicine (PubMed 18981485) · FDA documents · ClinicalTrials.gov NCT06948214 Primary source

Sources

• Nass et al. 2008, Annals of Internal Medicine (PubMed 18981485) · FDA documents · ClinicalTrials.gov NCT06948214
• FDA briefing document (media/183016)
• FDA briefing document (media/94155)
• ClinicalTrials.gov NCT06948214
• Lumos Pharma: LUM-201